A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors
Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
To determine the maximum tolerated dose or optimal biological dose, and the safety profile of
MEDI3617 when given as a single-agent or in combination with other chemotherapeutic agents in
subjects with advanced solid malignancies resistant to standard therapy.